Concepedia

Author

Charles Morris

AstraZeneca (United Kingdom)ORCID

Also Known As

C Morris, C. Morris, C.Q. Morris, Charles Morris, Charles Q. Morris, Claire G. Morris

25

Publications

3.4K

Citations

12

H-Index

15

Concepts

All Affiliations

AstraZeneca (United Kingdom)AstraZeneca (United States)Methodist HospitalNottingham City Hospital
CM

About

Charles Morris is an author at AstraZeneca (United Kingdom) specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

417

2

Pharmacology

4

4

417

3

Endocrinology

1

1

216

4

Obstetrics

1

1

216

5

Pathology

1

1

14

Charles Morris

×

8

Publications

2.6K

Citations

8

H-Index

YearCitations

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

Malcolm Ranson, Lisa A. Hammond, D. K. Ferry,

Journal of Clinical Oncology

2002

762

Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior Endocrine Therapy: Results of a North American Trial

C. Kent Osborne, John Pippen, Stephen E. Jones,

Journal of Clinical Oncology

2002

643

Comparison of Fulvestrant Versus Tamoxifen for the Treatment of Advanced Breast Cancer in Postmenopausal Women Previously Untreated With Endocrine Therapy: A Multinational, Double-Blind, Randomized Trial

Anthony Howell, J.F.R. Robertson, P. Abram,

Journal of Clinical Oncology

2004

424

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women

J.F.R. Robertson, C. Kent Osborne, Anthony Howell,

Cancer

2003

312

Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.

J.F.R. Robertson, Robert I. Nicholson, NJ Bundred,

PubMed

2001

216

Pharmacokinetics and Tolerability of the Orally Active Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Healthy Volunteers

Helen Swaisland, Alison Laight, Lesley E. Stafford,

Clinical Pharmacokinetics

2001

118

Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)

Charles J. Ryan, Walter M. Stadler, Bruce J. Roth,

Investigational New Drugs

2007

69

EGF receptor tyrosine kinase inhibitors as anti-cancer agents - pre-clinical and early clinical profile of ZD 1839

J.R. Woodburn, Charles Morris, Hanna Kelly,

Cellular & Molecular Biology Letters

1998

14

Page 1